Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, analysts from William Blair worried that adverse events are not tapering off as expected.

Scroll to Top